Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6)
Olalekan O. Oluwole(Vanderbilt University), Tom van Meerten(University Medical Center Groningen), Jaeyeon Kim(Sidney Kimmel Cancer Center), Catherine Thiéblemont(Université Paris Cité), Marie José Kersten(Hovon), Caron A. Jacobson(Dana-Farber Cancer Institute), Monique C. Minnema(University Medical Center Utrecht), Abhinav Deol(Wayne State University), Saran Vardhanabhuti, John M. Timmerman(Sheba Medical Center), Nancy L. Bartlett(Washington University in St. Louis), Dimitrios Tzachanis(Dana-Farber Cancer Institute), Irit Avivi(Tel Aviv Sourasky Medical Center), Rhine R. Shen(Broad Institute), Julie M. Vose(University of Nebraska Medical Center), Édouard Forcade(Hôpital Cardiologique du Haut-Lévêque), André Goy(Hackensack University Medical Center), Javier Muñoz(The University of Texas MD Anderson Cancer Center), Yi Lin, Umar Farooq(Wake Forest University), Peter A. McSweeney(Mesoblast (United States)), Sophie de Guibert(Centre Hospitalier Universitaire de Rennes), Yan Zheng, Patrick J. Stiff(Loyola University Medical Center)
Cited by 7
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k